术前放化疗对 T1 期低位直肠癌患者的肿瘤学结局的影响。
Oncological Outcomes of Pathological T1 Lower Rectal Cancer Patients With or Without Preoperative Chemoradiotherapy.
机构信息
Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan
Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
出版信息
In Vivo. 2020 Nov-Dec;34(6):3559-3564. doi: 10.21873/invivo.12199.
BACKGROUND/AIM: It remains unclear whether rectal cancers down-staged by preoperative chemoradiotherapy (CRT) have similar prognoses to those of the same stage without preoperative CRT. We compared prognoses of pT1 rectal cancer patients stratified by preoperative CRT.
PATIENTS AND METHODS
We retrieved data of patients with pathological T1 rectal cancer between 2003 and 2020. Patients were divided into the "ypT1 group" who received preoperative CRT following surgery and the "pT1 group" who underwent surgery alone. Factors associated with relapse-free survival (RFS) were investigated.
RESULTS
Among 86 patients, ypT1 and pT1 groups comprised 18 and 68 patients, respectively. There was no significant difference in RFS between the groups (p=0.19). Tumor location within 5 cm from the anal verge was associated with recurrence (hazard ratio: 0.13, p=0.034).
CONCLUSION
The prognosis of patients with ypT1 rectal cancer was similar to that of patients with pT1. Low tumor location was a poor prognostic factor.
背景/目的：术前放化疗（CRT）降期的直肠癌与未经术前 CRT 的同分期直肠癌的预后是否相似仍不清楚。我们比较了经术前 CRT 分层的 pT1 直肠癌患者的预后。
患者和方法
我们检索了 2003 年至 2020 年间病理 T1 直肠癌患者的数据。患者被分为“ypT1 组”，即术后接受术前 CRT，以及“pT1 组”，即仅接受手术。研究了与无复发生存（RFS）相关的因素。
结果
在 86 名患者中，ypT1 组和 pT1 组分别有 18 名和 68 名患者。两组的 RFS 无显著差异（p=0.19）。距离肛门缘 5cm 以内的肿瘤位置与复发相关（风险比：0.13，p=0.034）。
结论
ypT1 直肠癌患者的预后与 pT1 患者相似。低位肿瘤是预后不良的因素。
Zotero 插件